Felix Health launches generic semaglutide across Canada: what it means for GLP-1 access and cost

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Health Canada approved the first generic version of semaglutide — the active ingredient in Ozempic and Wegovy (Novo Nordisk) — on April 28, 2026, making Canada the first G7 country to authorize a generic GLP-1 receptor agonist injection. A second generic, from Toronto-based Apotex Inc., followed on May 1, 2026. Felix Health, a Canadian digital-health platform, announced on May 22, 2026 that it is now dispensing generic semaglutide to patients nationwide at a flat price of $150 CAD per month, with nearly 15,000 Canadians already on its waiting list.

For hormone-care and metabolic-health patients in Canada, the approvals mark a concrete shift in affordability. Brand-name Ozempic has typically cost between $200 and $450 CAD per month depending on province and provider, and it has rarely been covered by provincial drug plans for weight management (as opposed to Type 2 diabetes). At $150/month, generic semaglutide lowers the out-of-pocket barrier meaningfully — though provincial pharmacare coverage for the generic has not yet been confirmed across all jurisdictions, and patients should verify their plan's formulary before assuming reimbursement.

What this means in Canada

Health Canada authorized the first generic semaglutide injection from Dr. Reddy's Laboratories (India) after a full review of safety, efficacy, and quality data under its generic-drug approval pathway. The Apotex generic — notable because Apotex is a Canadian company headquartered in Toronto — followed three days later. Health Canada has stated that generic medications in Canada are typically 45–90% cheaper than their brand-name equivalents, though real-world pharmacy pricing varies.

Seven additional generic semaglutide applications remain under review by Health Canada as of late May 2026. Experts quoted in the Toronto Sun expect prices to fall further as more generics enter the market.

On provincial coverage: as of publication, no provincial or territorial drug benefit program — including Ontario's OHIP+ and Ontario Drug Benefit (ODB), Quebec's RAMQ, British Columbia's PharmaCare, or Alberta's AHCIP — has publicly confirmed that generic semaglutide is listed on its formulary for either diabetes or weight management. Brand-name Ozempic is covered for Type 2 diabetes under several provincial plans with appropriate criteria, but coverage for obesity or weight management indications remains inconsistent across Canada. Patients should contact their provincial drug plan directly or speak with a pharmacist to confirm current formulary status.

The Society of Obstetricians and Gynaecologists of Canada (SOGC) has not issued a specific position statement on generic semaglutide as of this writing. The Canadian Diabetes Association (Diabetes Canada) has long advocated for improved access to GLP-1 therapies for people living with Type 2 diabetes and obesity-related conditions.

In terms of digital-health access, Felix Health (a Canadian platform) is currently the most prominent provider publicly offering generic semaglutide. Other Canadian telehealth platforms — including Maple, Telus Health, Cleo (a Canadian women's-health platform), and Science & Humans (scienceandhumans.com) — have not yet publicly announced generic semaglutide offerings as of publication. US-based platforms such as Hone Health, Midi, and Winona do not serve Canadian patients and are not relevant here.

What changed

Before April 28, 2026, every semaglutide product available in Canada was a Novo Nordisk brand: Ozempic (approved for Type 2 diabetes) and Wegovy (approved for chronic weight management). Generic competition did not exist anywhere in the G7. Canada's approval of the Dr. Reddy's generic — ahead of the United States, the United Kingdom, Germany, France, Italy, and Japan — is a regulatory milestone.

The mechanism matters: semaglutide is a GLP-1 receptor agonist, a class of injectable drugs that mimic the glucagon-like peptide-1 hormone to lower blood sugar, slow gastric emptying, and reduce appetite. It is administered by subcutaneous injection once weekly. Health Canada's generic approval means the new products have demonstrated bioequivalence to the reference brand — they deliver the same active ingredient at the same dose with the same clinical effect, under the same safety profile.

The cost shift is significant. At $150/month from Felix Health, a patient paying out of pocket saves between $50 and $300 CAD per month compared to brand-name Ozempic pricing. Over a year, that is $600 to $3,600 CAD in potential savings — a meaningful difference for patients who have been rationing doses or forgoing treatment entirely due to cost.

What Canadian patients should know

If you are currently prescribed Ozempic or Wegovy, do not switch to a generic without speaking to your prescribing physician or pharmacist. While Health Canada's bioequivalence standard is rigorous, your provider should confirm that a switch is appropriate for your specific dose, injection device, and clinical situation. The injection pen devices for generics may differ from the brand-name pens you are accustomed to.

If you are newly seeking semaglutide, a prescription is required in Canada regardless of whether you access it through a walk-in clinic, a family physician, an endocrinologist, or a digital-health platform like Felix Health. Telehealth platforms can issue prescriptions after a clinical assessment, but they cannot prescribe without one.

Provincial coverage differences are real. A patient in Ontario with Type 2 diabetes may qualify for ODB coverage of brand-name Ozempic under existing criteria; whether that coverage extends automatically to the generic depends on whether the generic is listed on the ODB formulary — which had not been confirmed at time of publication. Quebec's RAMQ operates its own formulary independently. British Columbia's PharmaCare and Alberta's AHCIP similarly require separate formulary listings. Check with your pharmacist or provincial drug plan before assuming the generic will be reimbursed.

For patients using semaglutide for weight management rather than diabetes, provincial coverage remains the harder problem. Most provincial plans do not currently cover GLP-1 drugs for obesity indications, generic or brand. The lower cash price of the generic does not solve the coverage gap — it only reduces the out-of-pocket cost for those paying privately.

Limitations and open questions

Several things are not yet resolved. Health Canada has approved two generics, but neither has been listed on provincial formularies as of late May 2026 — formulary listing is a separate process from federal approval and can take months. The $150/month price from Felix Health is a single provider's launch price and may not reflect what community pharmacies charge once they begin stocking the generics.

Long-term post-market safety data specific to the generic formulations does not yet exist, though bioequivalence approval means the clinical evidence base from brand-name semaglutide trials applies. The SOGC has not weighed in on the use of generic semaglutide in populations with hormonal conditions such as polycystic ovary syndrome (PCOS), where GLP-1 drugs are sometimes used off-label. Health Canada has not issued guidance on switching between brand and generic formulations mid-treatment.

Finally, seven more generic applications are under review. Pricing will likely continue to fall — but the timeline for those approvals is not public.

---

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.